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Abstract
Background: Nitidine is thought to be the main active ingredient in several traditional anti-malarial remedies used
in different parts of the world. The widespread use of these therapies stresses the importance of studying this
molecule in the context of malaria control. However, little is known about its potential as an anti-plasmodial drug,
as well as its mechanism of action.
Methods: In this study, the anti-malarial potential of nitidine was evaluated in vitro on CQ-sensitive and -resistant
strains. The nitidine’s selectivity index compared with cancerous and non-cancerous cell lines was then determined.
In vivo assays were then performed, using the four-day Peter’s test methodology. To gain information about
nitidine’s possible mode of action, its moment of action on the parasite cell cycle was studied, and its localization
inside the parasite was determined using confocal microscopy. The in vitro abilities of nitidine to bind haem and
to inhibit b-haematin formation were also demonstrated.
Results: Nitidine showed similar in vitro activity in CQ-sensitive and resistant strains, and also a satisfying selectivity
index (> 10) when compared with a non-cancerous cells line. Its in vivo activity was moderate; however, no sign of
acute toxicity was observed during treatment. Nitidine’s moment of action on the parasite cycle showed that it
could not interfere with DNA replication; this was consistent with the observation that nitidine did not localize in
the nucleus, but rather in the cytoplasm of the parasite. Nitidine was able to form a 1-1 complex with haem in
vitro and also inhibited b-haematin formation with the same potency as chloroquine.
Conclusion: Nitidine can be considered a potential anti-malarial lead compound. Its ability to complex haem and
inhibit b-haematin formation suggests a mechanism of action similar to that of chloroquine. The anti-malarial
activity of nitidine could therefore be improved by structural modification of this molecule to increase its
penetration of the digestive vacuole in the parasite, where haemoglobin metabolization takes place.
Background
Malaria is a major cause of childhood mortality and
adult morbidity in many parts of the world. Recent esti-
mates indicate that more than 200 million clinical epi-
sodes of malaria and approximately about 1 million
deaths due to Plasmodium falciparum occur worldwide
annually. Resistance of this parasite to virtually all of the
currently available anti-malarial drugs is of great con-
cern; consequently, new, inexpensive drugs are urgently
needed to address the global burden of malaria. Natural
substances have provided the best anti-malarials that are
currently available. These anti-malarials, including arte-
misinin and quinine, as well as numerous molecules
derived from plants, are promising lead compounds that
combat malaria infection. Unfortunately, the efficacy of
many of these molecules has only been confirmed by in
vitro experiments on P. falciparum [1]. This is the case
for nitidine, an alkaloid found in several traditional
remedies from diverse endemic areas that had previously
been discovered and has been rediscovered in the last 50
years.
Nitidine was first isolated in 1959 from Zanthoxylum
nitidium (Rutaceae) [2]; it was found again approxi-
mately 40 years later in a traditional Kenyan anti-malar-
ial remedy [3] and was more recently discovered in
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from South America [4]. The widespread use of nitidine
stresses the importance of this molecule in the field of
malaria control.
Many biological properties have been ascribed to niti-
dine, including its use as an anti-microbial [5], anti-HIV
[6] analgesic and anti-inflammatory [7] agent. Cytotoxic
and anti-cancerous properties were also reported [8],
including nitidine-mediated inhibition of topoisomerase
I [9], which may indicate potentially important toxicity
and could rule out this molecule’s use as an anti-malar-
ial drug.
Further investigations concerning the anti-malarial activ-
ity of nitidine, with focus on its toxicity on different cells
lines, its in vitro activity on chloroquine-resistant P. falci-
parum strains, and its in vivo activity in a murine malaria
model were pursued. To obtain insight into nitidine’s
mechanism of action, its interaction with haemin and its
ability to inhibit b-haematin formation were studied.
Methods
Chemicals
All of the chemicals used in this study were obtained
from Sigma-Aldrich (Saint-Quentin, France). Nitidine in
its basic form was purified from Z. rhoifolium as pre-
viously described [4]. Basic nitidine was then dissolved
in chloroform with 10% methanol, and the addition of
concentrated hydrochloric acid at 0 C precipitated niti-
dine as a chloride salt. The precipitate was filtered,
rinsed with water and dried under a vacuum. Its struc-
ture (Figure 1) was confirmed by 1H-NMR and 13 C-
NMR mass spectrometry. Nitidine chloride appeared as
a pure compound on the
1H-NMR spectra, therefore its
purity can be considered superior to 95%. For biological
uses, nitidine chloride was dissolved as a stock solution
(10 mg/ml) in DMSO.
In vitro anti-plasmodial activity
The P. falciparum F-32-Tanzania chloroquine-sensitive
strain, FcM29 and FcB1-Columbia chloroquine-resistant
strains were cultured according to Trager and Jensen
[10], with modifications [11]. The cultures were syn-
chronized by a combination of magnetic concentration
and 5% D-sorbitol lysis (Merck, Darmstadt, Germany)
[12,13]. The F-32-Tanzania strain was considered to be
chloroquine-sensitive (chloroquine IC50: 38 ± 6 nM);
the FcM29 and FcB1-Columbia strains were considered
to be chloroquine-resistant (chloroquine IC50: 170 ± 32
nM and 230 ± 11 nM, 196 ± 31 nM, and > 100 nM,
respectively). Anti-plasmodial activity was determined by
the [
3H]-hypoxanthine (Amersham-France) incorpora-
tion method [14]. The resistance index was calculated as
follows: IC50 F32/IC50 FcB1 and IC50 F32/IC50 FcM29
The sensitivity of different stages of P. falciparum was
tested using the FcB1 strain. Serial dilutions of nitidine,
which were close to its IC50 determined previously on
this strain, were prepared. After synchronization over a
six-hour period (time between magnetic collection of
previous stages and sorbitol lysis after invasion), the
parasites were plated at ring stage in 24-well plates. The
drugs (nitidine and chloroquine as a control) were
added, and the plates were incubated for 8 h; the corre-
sponding wells were then washed while the drugs were
added into the new wells for another eight-hour incuba-
tion. The cultures were then incubated until the end of
the erythrocytic cycle plus an additional 24 h. Giemsa-
stained thin smears were made, and parasitaemia was
confirmed by the numeration of at least 10,000 erythro-
cytes [15].
In vitro cytotoxicity
The toxicity of nitidine was estimated using MCF-7 cells
(human breast carcinoma) and Vero cells (normal mon-
k e yk i d n e yc e l l s ) .T h e s ec e l l lines were cultured in the
same conditions as P. falciparum, except for the replace-
ment of 5% human serum with 10% foetal calf serum.
After the addition of nitidine at increasing concentra-
tions, cell growth was estimated by [
3H]-hypoxanthine
incorporation following a 48-h incubation and was com-
pared with a control sample that did not have additional
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Figure 1 Nitidine chloride.
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referred to as 100%) [15]. The selectivity index was cal-
culated as follows: IC50 FcB1/IC50 McF7 and IC50 FcB1/
IC50 Vero.
In vivo anti-malarial activity testing
The classic four-day suppressive in vivo assay was per-
formed using CD female mice according to European
legislation on laboratory animal use and care (EEC
directive 86/609). The mice (mean body weight: 20 ± 2
g) were infected with 10
6 Plasmodium vinckei petteri-
infected red blood cells [16] in RPMI on day 0. Groups
of five mice were treated intra-peritonally from days 0-3
with increasing doses (0.1 mg/kg to 20 mg/kg) of the
drug. On day 4, Giemsa-stained smears were made for
each mouse, and parasitaemia was estimated by visual
numeration of at least 5,000 erythrocytes. Mice treated
with RPMI alone served as negative controls, and mice
treated with chloroquine at various doses served as posi-
tive controls. Inhibition percentage was calculated using
the following formula: (control parasitaemia - parasitae-
mia with drugs)/(control parasitaemia) × 100.
Interaction with haem
The binding of nitidine with haemin chloride was
assessed using UV-Visible spectroscopy (Analitik Jena
Specord 205). Haemin chloride (Sigma 51280) was used
without further purification. The H2Ou s e dd u r i n gt h e
UV studies was freshly filtered milli-q water. To mini-
mize the aggregation of haemin on surfaces, only care-
fully washed glass and quartz were used (glass volumetric
flasks, glass pipettes, and microsyringes, quartz UV cuve),
as previously described [17]. The UV interaction experi-
ments were conducted in a 40/60 DMSO/H2Om i x t u r e
buffered with HEPES, as described by Egan et al. [18],
with modifications. Haemin solution (2 μM, sol C) was
titrated by the addition of increasing amounts of a solu-
tion of nitidine mixed with haemin (sol D) to ensure a
constant haemin concentration during titration. The
solutions were prepared in volumetric flasks. Mother
solutions of haemin (1 mM, sol A) and nitidine (1 mM,
sol B) in DMSO were freshly prepared. To obtain the
haemin solution (sol C), sol A (20 μl) was mixed with
DMSO (4 ml) and 0.2 M HEPES Buffer (0.5 ml), and the
volume was adjusted to 10 ml with water. To obtain the
titration solution (sol D), sol A (10 μl) and sol B (1 ml)
were mixed with DMSO (2 ml) and 0.2 M HEPES Buffer
(0.5 ml), and the volume was adjusted to 5 ml with water.
Two ml of haemin solution (sol C) were poured into a
quartz UV cuvette, and increasing amounts of titrant
(sol D) were added (5 μl was added 42 times, 10 μlw a s
added ten times, and 50 μl was added ten times).
Absorbance at 402 nm was recorded after each addi-
tion of titrant solution (sol D) and agitation of the
cuvette content. As nitidine absorbed at 402 nm, a
blank titration of nitidine under the same conditions as
described above was prepared, but without haemin. The
variation in absorbance (ΔA) for each point of the titra-
tion curve corresponded to the value obtained during
the titration (A1) minus the value obtained during the
blank experiment (A2), minus the value of haemin solu-
tion when no ligand was added (A = A1 - A2 - A(0)).
This binding experiment was also performed using
chloroquine diphosphate (in water) as a positive control.
All of the titration experiments were performed in
triplicate.
Stoicheiometry and binding constants of the haem-
nitine and haem-chloroquine complexes were calculated
from titration curves using the SPECFIT32
® software.
Inhibition of b-haematin formation
The protocol described by Deharo et al. [19] was fol-
lowed. Briefly, in a normal, non-sterile flat-bottom 96-
well plate, 50 μlo f0 . 5m g / m lh a e m i nc h l o r i d e( S i g m a
51280) freshly dissolved in DMSO was added to 100 μl
acetate buffer (c = 0.2 M, pH = 4.4) and to 50 μlo fa
solution of nitidine chloride dissolved in DMSO (c = 1;
0.5; 0.1; 0.05; 0.01 mg/ml). The plate was agitated and
left at 37 C for 18 h. Then the plate was centrifuged at
550 g for 8 min. The supernatant was removed by vigor-
ously flipping the plate upside down. Then 200 μl
DMSO was added to wash the pellet, the plate was agi-
tated and centrifuged at 550 g for 8 min, and the super-
natant was removed again. This washing procedure was
repeated twice. Then the pellet was dissolved in 200 μl
0.1 M sodium hydroxide solution, and the absorbance
w a sr e a da t4 0 5n M .T h er e s u l t sw e r ee x p r e s s e da sp e r
cent of inhibition compared to a blank experiment
(DMSO). Each concentration was tested in triplicate.
The positive control was quinine hydrochloride in
DMSO. Each experiment was performed three times.
Microscopy
The fluorescent properties of nitidine (excitation l:3 6 6
and 380 nm, emission peaks 440 (blue) and 540 (green)
nm) were used to determine its localization and concen-
tration in red blood cells. Approximately 100 μl of each
culture was washed three times in complete culture
medium, and nitidine was added at increasing concen-
trations (52 to 1040 μM, where the optimum was 120
μM). After a two-hour incubation, three washes were
performed with complete culture medium, and then dif-
ferent dyes were added (Lysotraquer
® red (5 μM) and
Draq5
® (5 μM)). Following an additional 30-min incuba-
tion, three washes using PBS were performed, and the
culture was mounted for microscopic examination onto
glass slides. For microphotography, glass slides were
coated with poly-L-lysine (Sigma) prior to deposition of
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(Eclipse E 400) microscope with DAPI and FITC filters.
For confocal microscopy, a Leica sp2 AOBS device with
a 405-nm laser diode and a Helium/Neon laser (543 nm
ray and 633 nm ray) was used. None of the pictures
were altered using the computer, with the exception of
a mathematical superposition that was performed using
Paint Shop Pro
® software.
Results
The anti-plasmodial activity of nitidine was evaluated on
three strains of P. falciparum with different sensitivities
to chloroquine (Table 1). The values of IC50 for nitidine
ranged from 0.49 to 0.80 μM .T h er e s i s t a n c ei n d e x( R I )
of nitidine was lower than the RI of chloroquine (1.55
and 0.95 for F32/FcB1 and F32/FcM29, respectively, ver-
sus more than 4 for chloroquine, Table 1).
In an attempt to determine nitidine’sm o m e n to f
action during the erythrocytic cycle, various concentra-
tions of nitidine were tested on a highly synchronized
culture of P. falciparum (FcB1 strain). At concentrations
ranging from one tenth to ten times the IC50, the high-
est inhibition of P. falciparum growth was obtained dur-
ing the two first thirds of the cycle, with a maximum
inhibition between hours 8 and 24 (Figure 2). Through-
out the same experiments, when nitidine was added
throughout the cycle, the observed values were similar
to those obtained by [
3H]-hypoxanthine incorporation
(IC50 close to 0.52 μM).
Nitidine’s cytotoxicity was then determined using two
cell lines, MCF-7 and Vero. The IC50 for MCF-7 was
close to the IC50 observed for P. falciparum and was
much higher for Vero cells (SI 0.74 and 26.3
respectively).
Because Vero cells are normal (non-transformed cells),
the toxicity observed on this cell line was low enough to
perform an in vivo assay (Table 2). In the classic four-
day in vivo suppressive test, parasitaemia decreased
enough to determine the ED50 of nitidine using only
two doses (18.9 mg/kg/day over four days). The positive
control, chloroquine, displayed an ED50 value of 5 mg/
kg/day over four days.
In the haem-binding experiment, a good fit of the
experimental titration curves with the calculated curves
was obtained for nitidine and chloroquine when study-
ing the formation of a 1-1 haem-molecule complex.
This finding was in agreement with the literature [18].
With this model, a binding log K value of 5.17 ± 0.02
was obtained for chloroquine and 4.4 ± 0.3 for nitidine.
The log K value for chloroquine in the literature is 5.5
[18]. However it can be noticed that a model incorpor-
ating the formation of both 1-1 and 2-1 haem-molecule
complexes slightly improved the fit for chloroquine and
also provided a good fit for nitidine.
In the in vitro inhibition of b-haematin formation
assay, an IC50 of 18 ± 7 μM for nitidine was found,
which was better than the value obtained for the qui-
nine-positive control (78 ± 20 μM) and was in the same
range as the value published for chloroquine (28 ± 5
μM) [19].
Microscopic analysis demonstrated that nitidine pre-
ferentially concentrated in parasitized red blood cells
(Figure 3) independent of parasite stage. In an attempt
to determine the precise intra-parasite localization, co-
staining followed by confocal microscopy analysis was
performed. After staining with nitidine, a double stain-
ing with digestive vacuole specific Lysotracker
® and
nucleus specific draq5
® was performed (Figure 4 and 5).
The resulting images demonstrated that nitidine did not
settle in these two compartments. The fluorescence
(corresponding to nitidine) was present in the whole
parasite cytoplasm rather th a ni nar e s t r i c t e dc o m p a r t -
ment. A range of nitidine concentrations was prepared
in order to link fluorescence intensity (measured by
confocal microscopy) to nitidine concentration. When
the initial concentration of nitidine in the culture med-
ium was 120 μM, the fluorescence intensity in the para-
site was 5.5 mM.
Discussion
Nitidine and fagaronine, another benzo[c]phenanthri-
d i n e ,h a v eb e e nd e s c r i b e da st h ep r i n c i p l ea c t i v ea n t i -
malarial compounds present in several traditional reme-
dies and plants from different parts of the world
[3,4,21]. Only one study focuses on the synthesis of
anti-malarial benzo[c]phenanthridines [22]. In that con-
text, studying the anti-malarial potency of nitidine was
of potential interest. First, the in vitro anti-plasmodial
activity of nitidine was independent of the chloroquine-
resistance status of the Plasmodium strain (Table 1).
The F32 strain has wild-type PfCRT, whereas FcB1 and
FcM29 carry the K76T mutation; the latter strain carries
numerous mutations that enhance CQ-resistance in
PfMDR [23]. This means that nitidine is insensitive to
Table 1 In vitro activity (IC50 in μM) of tested drugs on
Plasmodium falciparum in MCF7 and Vero cells
Cell lines Nitidine Chloroquine Doxorubicin
F32 0.52 ± 0.1 0.051 NT
FcB1 0.80 ± 0.28 0.141 NT
FcM29 0.49 ± 0.1 0.22 NT
RI
a 1.55 and 0.95 4.3
MCF-7 0.23 ± 0.03 > 50 0.42 ± 0.05
Vero 8.16 ± 1.04 > 50 6.4 ± 0.9
SI
b 0.74 and 26.3
a: Resistance index: F32/FcB1 and F32/FcM29
b: Selectivity index: FcB1/McF7 and FcB1/Vero
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quine-resistant Plasmodium strains.
Because this molecule has been described as a poten-
tial anti-cancer agent, it was intersesting to assess its
anti-plasmodial selectivity. Compared to MCF-7 cells,
which derive from a cancerous cell line, no anti-plasmo-
dial selectivity was observed; however, when compared
to Vero cells, which derive from a non-cancerous mam-
malian cell line, the selectivity index was almost 30
times higher (SI = 26).
This finding highlights nitidine’s ability to interfere
with cell growth processes through a mechanism other
than topoisomerase I inhibition [5]. This also seems to
correspond with the low level of plasmodial topoisome-
rase I activity that was observed in the youngest stages
of intraerythrocytic development of the parasite, which
was in contrast to the high nitidine activity observed at
the same stage [24].
This good selectivity index justified an in vivo experi-
ment. In the four-day Peter’s suppressive test, nitidine
displayed an ED50 of 18.9/mg/kg/day over four days.
This value was higher than that obtained for the chloro-
quine control (ED50 o f5 / m g / k g / d a yo v e rf o u rd a y s ) ;
however, no mice died during treatment, so the acute
DL50 was not reached at 20 mg/kg/day, which was the
highest dose. Thus, the low toxicity observed with Vero
cells was confirmed.
The action of nitidine was highest during the first two
thirds of the P. falciparum erythrocytic cycle (between
hours 8 and 24), when the production of plasmodial
RNA and protein were highest [20]. Therefore, nitidine
did not interfere directly with plasmodial DNA synth-
esis, which occurs between hours 32 and 40 [20]. As
anti-cancer activities of nitidine have been correlated
with the ability of this molecule to intercalate into DNA
[25] and to inhibit topoisomerase I [9], it can be
hypothesized that nitidine could have a different and
more specific anti-plasmodial mode of action. It can
also be thaught that with its planar and aromatic struc-
ture, nitidine could interact with haem and exert its
anti-plasmodial activity by inhibiting haemozoin forma-
tion inside the food vacuole of the parasite. This is now
aw i d e l yn o t e dm o d eo fa c t i o nf o rc h l o r o q u i n e ,a n d
Figure 2 Nitidine’s moment of action on the erythrocytic cycle of Plasmodium falciparum. A parasite culture synchronized over a six-hour
period was subjected to an eight-hour pulse of nitidine at IC50 (grey bars), 1/10 (dark grey) and 10 times the value (white bars). Major events
along the erythrocytic cycle are summarized. The dotted line shows protein synthesis, and the solid black line shows DNA synthesis [20].
Table 2 In vivo activity of nitidine in a four-day
suppressive test (ED50)
n Mean parasitaemia ± SD inhibition
Control 10 69.8 ± 12.8
CQ 10 mg/kg/d 5 1.1 ± 1.2 98%
CQ 1 mg/kg/d 5 78.9 ± 8.2 0%
Nitidine 10 mg/kg/d 5 62.1 ± 8.9 11%
Nitidine 20 mg/kg/d 5 28.5 ± 10.4 59%
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oped based on a similar mechanism of action [26,27]. In
vitro measurement of haem’s interaction with anti-plas-
modial molecules was described by Egan et al. [18].
Using a similar methodology, it was demonstrated that
nitidine was able to form 1-1 complexes with haem,
similar to chloroquine. The log K value obtained for
these complexes showed that the nitidine-haem complex
was less stable than the chloroquine haem-complex, but
the affinity of nitidine for haem was higher than the affi-
nities of quinine or mefloquine for haem, which were
also reported by Egan.
Furthermore, it was evidenced that nitidine was able
to inhibit b-haematin formation with the same potency
as chloroquine in an in vitro test.
However, the localization experiment using confocal
microscopy showed that nitidine was concentrated in
the whole cytoplasm of P. falciparum and was not loca-
lized in the digestive vacuole where crystallization of
haemozoin takes place. This fluorescence repartition
may be due to the absence of nitidine in the digestive
vacuole, or to the quenching of fluorescence when niti-
dine is complexed with haem, as previously reported for
some cryptolepine derivatives [28]. Lastly, according to
Ginsburg et al. [29] and Platel et al. [30], haem would
be partially degraded in the plasmodial cytosol by GSH
(reduced glutathione). Egan et al. [31] questioned this
hypothesis but could not exclude the possibility that a
small fraction of haem could be degraded in this loca-
tion, thus providing the parasite’s iron requirement.
Figure 3 Nitidine concentration in parasitized red blood cells (optical microscopy). The drug was added at a final concentration of 120
μM. a: direct examination (bar: 10 μm), b: FITC filter, c: merge. The drug appeared to be concentrated in the parasite inside the parasitized RBC.
Ă  ď 
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Figure 4 Confocal microscopy analysis after double staining cells with nitidine and lysotracker
®.a : staining with 120 μM nitidine, b:
staining with 5 μM lysotracker
®, c: merge, d: daylight. The repartition of nitidine was not similar to that of Lysotracker
®, a stain that concentrates
in the food vacuole of the parasite.
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impairs the interaction between GSH and haem in the
cytoplasm of the parasite instead of by direct action on
the biocrystallization process in the vacuole.
Finally, nitidine was not localized in the nucleus and
therefore does not interact with parasite DNA.
Structural modifications of nitidine could be used to
improve its capacity to accumulate inside the food
vacuole. It is well known that chloroquine accumulates
inside the acidic food vacuole because of its basic amino
side chain. Therefore, the synthesis of benzo[c]phenan-
thridine-bearing amino side-chains is currently under-
way. This strategy has been successfully employed in the
xanthone and acridone series [27,32,33] and also in the
cryptolepine and neocryptolepine series [28,34].
Conclusion
This detailed study of the anti-plasmodial activity of niti-
dine showed that this known anti-plasmodial molecule,
which is present in several traditional anti-malarial reme-
dies, can be considered an interesting lead compound.
Nitidine was active in vitro on chloroquine-sensitive and
-resistant Plasmodium strains and displayed an adequate
selectivity index when tested on a non-cancerous mam-
malian cell line. In vivo evaluation of nitidine showed
that it had moderate anti-malarial activity and displayed
no sign of acute toxicity. Its ability to bind haem and
inhibit b-haematin formation in vitro suggests a possible
chloroquine-like mechanism of action and paves the way
for further structural optimization.
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